EPOバイオ後続品(バイオシミラー) – エリスロポエチン市場の先行き

◆英語タイトル:EPO Biosimilars - The Future of Erythropoietin Market
◆商品コード:RNCS60908
◆発行会社(調査会社):RNCOS
◆発行日:2016年8月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD600 ⇒換算¥68,400見積依頼/購入/質問フォーム
Multi UserUSD1,000 ⇒換算¥114,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規販売代理店です。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。
※本調査レポートでは、EPOバイオ後続品(バイオシミラー)市場について調査・分析し、以下の構成でお届けいたします。

1. アナリストの見解
2. 調査方法
3. 産業動向および成長要因
4. 産業の課題
5. タンパク質治療の世界市場
6. エリスロポエチン市場の概要
7. エリスロポエチンの世界市場見通し
8. 市場セグメンテーション
9. 地域別エリスロポエチンの世界市場
10. エリスロポエチンのパイプライン分析
11. 市場勢力図
【レポートの概要】

Erythropoietin is a hormone produced by healthy kidneys. This hormone prompts the bone marrow to make the red blood cells, which then carry oxygen throughout the body. Erythropoietin is used to treat anemia resulting from kidney failure or cancer treatment. It is considered to be an alternative to blood transfusions. Over the last few years, the global erythropoietin industry has been showing a sluggish growth due to patent expiry of biologic drugs. However, the biosimilar versions of these drugs are expected to witness precipitous growth owing to their low cost.
As per RNCOS report “EPO Biosimilars – The Future of Erythropoietin Market”, the global erythropoietin market is anticipated to reach an approximate value of US$ 7 Billion by 2020. This report provides a detailed analysis of the current and future market scenario of the global erythropoietin market. The report highlights biosimilar erythropoietin at various stages of clinical development. In addition, the report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth.

The global erythropoietin market has been segmented into biologic and biosimilar erythropoietin markets. The report also highlights the various biologic and biosimilar erythropoietin drugs currently available in the market. Furthermore, the global erythropoietin market has also been segmented on the basis of their applications. Based on geography, the report divides the market into the US, Europe, and Asia-Pacific.

The last section of the report discusses about the prominent players in global erythropoietin market. Market share analysis of these players is also provided in the report. A brief business overview and financial information about each of these players has been provided along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global erythropoietin market.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Industry Trends and Drivers
3.1 Biosimilars Opens Array of Opportunity for Market Growth
3.2 Growing Geriatric Population
3.3 Increasing Incidences of Chronic Diseases
3.4 Ability to Curb Healthcare Cost
4. Industry Challenges
4.1 High Prices
4.2 Stringent Regulatory Processes
4.3 Threat from Substitutes
5. Global Protein Therapeutics Market
5.1 Protein Therapeutics Market Vs Pharmaceutical Market
5.2 Current and Future Market Analysis for 2022
5.3 Market Segmentation
6. Erythropoietin Market – Introduction
7. Global Erythropoietin Market Outlook to 2022
8. Market Segmentation
8.1 By Type
8.1.1 Biologic
8.1.2 Biosimilar
8.2 By Application
8.3 By Drug
9. Global Erythropoietin Market by Geography
9.1.1 US
9.1.2 Europe
9.1.3 Asia-Pacific
10. Pipeline Analysis of Erythropoietin
11. Competitive Landscape
11.1 Share of Major Players
11.2 Key Players Analysis
11.2.1 Amgen Inc.
11.2.2 Johnson & Johnson
11.2.3 Roche Group
11.2.4 Pfizer Inc.
11.2.5 Novartis

List of Figures:

Figure 3-1: Global – Population above 60 Years (Billion), 2013 & 2050
Figure 3-2: Global – Incidences of Cancer (Million), 2015 & 2025
Figure 3-3: US – Adults (30 Years or Above) Suffering from Chronic Kidney Disease (%), 2015, 2020 & 2030
Figure 5-1: Global – Protein Therapeutics vs. Pharmaceutical Market (Billion US$), 2015
Figure 5-2: Global – Protein Therapeutics Market (Billion US$), 2015 & 2022
Figure 5-3: Global – Protein Therapeutics Market by Segment (%), 2015
Figure 5-4: Global – Forecast for Protein Therapeutics Market by Segment (%), 2022
Figure 7-1: Global – Erythropoietin Market (Billion US$), 2015 & 2022
Figure 7-2: Global – Share of Biologic and Biosimilar Erythropoietin (%), 2015
Figure 7-3: Global – Forecast for Share of Biologic and Biosimilar Erythropoietin (%), 2022
Figure 8-1: Global – Biologic Erythropoietin Market (Billion US$), 2015 & 2022
Figure 8-2: Global – Biosimilar Erythropoietin Market (Million US$), 2015 & 2022
Figure 8-3: Global – Share of Therapeutic Applications of Erythropoietin (%), 2015
Figure 9-1: Global – Share of Erythropoietin Market by Geographic Regions (%), 2015
Figure 9-2: US – Erythropoietin Market (Billion US$), 2015 & 2022
Figure 9-3: Europe – Erythropoietin Market (Billion US$), 2015 & 2022
Figure 9-4: Asia-Pacific – Erythropoietin Market (Billion US$), 2015 & 2022
Figure 10-1: Global – Erythropoietin Pipeline Analysis by Type (%), 2015
Figure 10-2: Global – Erythropoietin Pipeline Analysis by Phase (%), 2015
Figure 11-1: Global – Share of Key Players in Erythropoietin Market (%), 2015

List of Tables:

Table 8-1: Global – Biologic Erythropoietin Drugs and Their Sales
Table 10-1: Global – Erythropoietin Product Pipeline
Table 11-1: Amgen Inc. – Total Company Revenue (Billion US$), 2013, 2014 & 2015
Table 11-2: Amgen Inc. – Commercialized Erythropoietin Products
Table 11-3: Amgen Inc. – Erythropoietin Product Sales (Billion US$), 2013, 2014 & 2015
Table 11-4: Johnson & Johnson – Total Company Sales (Billion US$), 2013, 2014 & 2015
Table 11-5: Johnson & Johnson – Commercialized Erythropoietin Products
Table 11-6: Johnson & Johnson – Erythropoietin Product Sales (Billion US$), 2013, 2014 & 2015
Table 11-7: Roche – Total Company Revenue (Billion US$), 2013, 2014 & 2015
Table 11-8: Roche – Commercialized Erythropoietin Products
Table 11-9: Roche – Erythropoietin Product Sales (Billion US$), 2013, 2014 & 2015
Table 11-10: Pfizer Inc. – Total Company Revenue (Billion US$), 2013, 2014 & 2015
Table 11-11: Pfizer Inc. – Commercialized Erythropoietin Products
Table 11-12: Novartis – Total Company Sales (Billion US$), 2013, 2014 & 2015
Table 11-13: Novartis – Commercialized Erythropoietin Products



★調査レポート[EPOバイオ後続品(バイオシミラー) – エリスロポエチン市場の先行き]販売に関する免責事項
★調査レポート[EPOバイオ後続品(バイオシミラー) – エリスロポエチン市場の先行き]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆